MASH: Diagnosis and Treatment Response Monitoring
Nov
2026
Description
This session reviews non-invasive diagnostic and monitoring tools for MASH, including novel imaging, cfDNA methylation, and composite scores for identifying fibrosis and disease progression.
Presentations
11:00 AM
- 11:15 AM
Convention Center - Bluebird Ballroom 1A
Spleen size correlates with increased liver stiffness measurement on MRI but has low positive predictive value for cirrhosis in MASLD
Kyle Rodrigues, BS | Abstract Presenter
11:15 AM
- 11:30 AM
Convention Center - Bluebird Ballroom 1A
Plasma cfDNA Methylation Enables Non-Invasive Snapshot of Liver Pathway Activity, Cell Composition, and Fibrosis Stage
Anna Mae E Diehl, MD, FAASLD | Abstract Presenter
11:30 AM
- 11:45 AM
Convention Center - Bluebird Ballroom 1A
MRI-PDFF plus AST identifies pediatric MASH, and longitudinal MRI-PDFF reduction predicts histologic response
Laurin Koenke | Abstract Presenter
11:45 AM
- 12:00 PM
Convention Center - Bluebird Ballroom 1A
Ruling Out Cirrhosis in Patients with ELF test 9–10.8 and VCTE LSM 10–20 kPa (High-Risk MASLD)
Mazen Noureddin, MD, , MHSc, FAASLD | Abstract Presenter
12:00 PM
- 12:15 PM
Convention Center - Bluebird Ballroom 1A
MAPS: A new Non-invasive Score for Identifying MASH and Predicting Disease Progression
Yousif Alyousifi, PhD | Abstract Presenter
12:15 PM
- 12:30 PM
Convention Center - Bluebird Ballroom 1A
Heritability of the serum proteome and shared genetic architecture with steatosis and fibrosis: A twin study.
Maria Mironova, MD, MHSc | Abstract Presenter
